Literature DB >> 9870475

Assessment of ultrasound guided percutaneous ethanol injection and parathyroidectomy in patients with tertiary hyperparathyroidism.

S Fletcher1, N S Kanagasundaram, H C Rayner, H C Irving, R C Fowler, A M Brownjohn, J H Turney, E J Will, A M Davison.   

Abstract

BACKGROUND: Tertiary hyperparathyroidism continues to cause significant morbidity in patients with chronic renal failure. This is frequently resistant to medical management and may ultimately require a surgical parathyroidectomy. Recent studies have reported upon the technique of percutaneous ethanol ablation for both primary and tertiary hyperparathyroidism. In this study we report on a 5 year experience using ethanol injection and compare the results with surgical parathyroidectomy.
METHODS: A prospective study in 39 patients with tertiary hyperparathyroidism, 25 were dialysis dependent and 14 had a functioning renal allograft. Twenty-two patients underwent percutaneous fine needle ethanol injection (PFNEI) and 17 underwent surgical parathyroidectomy.
RESULTS: A > 30% reduction in intact parathyroid hormone (iPTH) was achieved in 11 of 22 patients undergoing PFNEI after a mean of 1.8 +/- 1.4 injections per gland. In four patients, symptomatic hyperparathyroidism recurred and they required further PFNEI or surgical parathyroidectomy at 17, 28, 46, and 48 months later. There was no significant reduction in iPTH in 11 patients following PFNEI after a mean of 2.5 +/- 1.3 injections per gland. They all required a subsequent surgical parathyroidectomy for symptomatic hyperparathyroidism. Four patients developed a laryngeal nerve palsy following PFNEI, two of which were permanent. Seventeen patients underwent successful surgical parathyroidectomy as a primary procedure.
CONCLUSION: Whilst PFNEI is successful in primary hyperparathyroidism, when typically only one adenoma is present, the effectiveness of PFNEI is unpredictable and the long term results are poor compared with those of surgical parathyroidectomy in tertiary hyperparathyroidism. The procedure is not without complications and makes subsequent surgery more difficult. Therefore it can only be recommended for patients with a known single parathyroid gland such as patients in whom hyperparathyroidism has recurred following a previous surgical subtotal parathyroidectomy and who are unsuitable for further surgery.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9870475     DOI: 10.1093/ndt/13.12.3111

Source DB:  PubMed          Journal:  Nephrol Dial Transplant        ISSN: 0931-0509            Impact factor:   5.992


  6 in total

1.  Success of endoscopic ultrasound-guided ethanol ablation of pancreatic cysts: a meta-analysis and systematic review.

Authors:  Manasa Kandula; Harsha Moole; Michael Cashman; Fritz H Volmar; Matthew L Bechtold; Srinivas R Puli
Journal:  Indian J Gastroenterol       Date:  2015-06-25

2.  Long-term follow-up of patients with tertiary hyperparathyroidism treated by resection of a single or double adenoma.

Authors:  Peter F Nichol; James R Starling; Eberhard Mack; Jason J Klovning; Bryan N Becker; Herbert Chen
Journal:  Ann Surg       Date:  2002-05       Impact factor: 12.969

3.  Assessment of parathyroid glands in hemodialysis patients by using color Doppler sonography.

Authors:  Umit Aksoy Ozcan; Ilay Oktay
Journal:  Eur Radiol       Date:  2009-05-27       Impact factor: 5.315

4.  Ethanol lavage of 14 mucinous cysts of the pancreas: A retrospective study in two tertiary centers.

Authors:  Fabrice Caillol; Laurent Poincloux; Erwan Bories; Emanuelle Cruzille; Christian Pesenti; Claude Darcha; Flora Poizat; Genevieve Monges; Jean-Luc Raoul; Gilles Bommelaer; Marc Giovannini
Journal:  Endosc Ultrasound       Date:  2012-04       Impact factor: 5.628

5.  Indication and efficacy of PEIT in the management of secondary hyperparathyroidism.

Authors:  Fumihiko Koiwa; Takeshi Hasegawa; Reika Tanaka; Takatoshi Kakuta
Journal:  NDT Plus       Date:  2008-08

6.  Efficacy and safety of radiofrequency ablation versus parathyroidectomy for secondary hyperparathyroidism in dialysis patients: a single-center retrospective study.

Authors:  Mian Ren; Danna Zheng; Juan Wu; Yueming Liu; Chengzhong Peng; Wei Shen; Bo Lin
Journal:  Sci Rep       Date:  2022-06-18       Impact factor: 4.996

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.